12 citations
,
July 2011 in “European Journal of Dermatology” The authors concluded that VSCAPSI, a videodermoscopy-based assessment tool, provides evidence for early diagnosis, differential diagnosis, follow-up, and screening of scalp psoriasis.
2 citations
,
March 2016 in “The Journal of Dermatology” The researchers reported that the facial Psoriasis Log-based Area and Severity Index (fPLASI) more reliably and sensitively captured clinical improvement in facial psoriasis than the existing facial Psoriasis Area and Severity Index (fPASI).
1 citations
,
April 2024 in “Skin research and technology” This clinical trial found that topical rosuvastatin and melatonin creams significantly reduced the severity of mild to moderate plaque psoriasis over 12 weeks, with a satisfactory safety profile.
8 citations
,
June 2021 in “Frontiers in Medicine” This study reported that the combination of a 308-nm excimer lamp and 10% liquor carbonis detergens significantly improved scalp psoriasis symptoms compared to the excimer lamp alone, with more patients achieving 75% reduction in their Psoriasis Scalp Severity Index.
July 2023 in “Journal of exploratory research in pharmacology” In this case report, a 47-year-old man with extensive psoriasis saw significant improvement in scaling and itching after using a new lotion containing clobetasol and other ingredients for one week, but further research is needed to confirm these findings.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” This study reports a case where a patient with both psoriasis and alopecia universalis experienced regrowth of scalp and body hair after treatment with Deucravacitinib, a TYK2 inhibitor, suggesting potential effectiveness but recommending controlled studies to confirm this finding.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.
February 2010 in “Journal of The American Academy of Dermatology” This study found that nonobese women with idiopathic hirsutism exhibited lower nitrite/nitrate concentrations and higher fibrinogen levels compared to control subjects, but these were similar to levels in women with polycystic ovary syndrome.
5 citations
,
May 2019 in “Archives of Dermatological Research” This study reported that narrowband UVB treatment significantly increased WNT7B, WNT10B, and TCF7L2 gene expression in lesional skin of psoriasis patients, suggesting these genes may play a role in psoriasis pathogenesis.
8 citations
,
April 2006 in “Acta dermato-venereologica” Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.
October 2024 in “Stem Cell Research & Therapy” This study found that CGF may be effective in reducing inflammation and improving skin conditions in psoriasis, particularly in patients resistant to other treatments.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
5 citations
,
April 2019 in “Dermatologic therapy” This case report described a 67-year-old man with moderate psoriasis who developed persistent generalized hypertrichosis after 4 months of treatment with secukinumab.
May 2026 in “Advanced Pharmaceutical Bulletin” In this study, black cumin oil-based nanostructured lipid carriers enhanced the delivery and effectiveness of fluticasone for psoriasis in a mouse model, improving skin targeting, inflammation reduction, and permeability compared to standard cream.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This case report describes a 33-year-old male with treatment-resistant psoriasis who experienced complete resolution of symptoms and hair regrowth after following an integrated Shodhana-Shamana chikitsa regimen, with no relapse noted at follow-up, suggesting its potential for sustainable Ekakustha management.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This case report observed that an integrated Shodhana-Shamana treatment protocol effectively managed treatment-resistant Ekakustha (plaque psoriasis), resulting in complete symptom resolution and no relapse at follow-up.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
May 2015 in “Journal of The American Academy of Dermatology” This study suggests that blood microarray biomarkers may help predict individual treatment response in psoriasis patients, highlighting a distinct blood signature related to inflammation, interferon, and myeloid lineage transcripts.
In this study, botulinum toxin type A injections reduced the severity of treatment-resistant scalp psoriasis in more patients compared to placebo over a 12-week period.
18 citations
,
January 2021 in “Theranostics” This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.
November 2022 in “Journal of Investigative Dermatology” This study found that the immunological characterization of ichthyoses as psoriasiform or atopic patterns could help improve treatment, highlighting the need for targeted therapies to address itch and skin inflammation.
July 2009 in “Medical & surgical dermatology” Low-dose acitretin helps nail psoriasis, stem cells may treat scarring alopecia, Chinese men have lower baldness rates, lateral foldplasty is good for ingrown toenails, hair diameter helps diagnose female baldness, childhood trauma linked to alopecia areata, certain hair-weaving leads to scalp conditions in African American women, and new methods for hair research and understanding hair and sweat gland development were introduced.
November 2024 in “Journal of Investigative Dermatology” Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.
2 citations
,
January 2012 Androgenetic alopecia is the only hair loss condition with specific diagnostic criteria in trichoscopy.
June 2026 in “International Journal of Ayurveda and Pharma Research” This study documented a case where Ayurvedic treatments for plaque psoriasis significantly reduced the severity of symptoms, as measured by an 84% improvement in the Psoriasis Area and Severity Index score from 6.5 to 1.04.
June 2021 in “Egyptian Journal of Dermatology and Venereology” This study found that psoriasis, acne, and androgenetic alopecia are associated with an atherogenic lipid profile, suggesting an increased risk of atherosclerosis and cardiovascular disease, especially among psoriasis patients.
January 2024 in “JEADV Clinical Practice” This study from the Danish Skin Cohort found that patients with alopecia areata, followed by those with hidradenitis suppurativa, were willing to spend the most daily time on treatment, reflecting possible unmet needs, and that this willingness correlated with disease severity across different dermatological conditions.
June 2024 in “British Journal of Dermatology” In this prospective observational study of 96 dermatomyositis patients, 47 showed scalp involvement, with significant symptoms like scalp inflammation, itching, and hair loss linked to myositis-specific antibodies. The study highlighted unique dermatopathological features in the scalp and emphasized the considerable morbidity caused by scalp dermatomyositis.
August 2023 in “Journal of Education, Health and Sport” This study reviewed current knowledge on Traditional Chinese Medicine, finding that Chinese herbs may reduce chronic urticaria activity, psoriasis severity, benign thyroid nodules, and improve β-cell function in diabetes. The authors noted the need for further research and the development of high-quality TCM pharmaceuticals.
104 citations
,
August 2008 in “Clinics in Dermatology” This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.